+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Stivarga"

Colorectal Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis Type, By Application, By Region, by Competition - Product Thumbnail Image

Colorectal Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis Type, By Application, By Region, by Competition

  • Report
  • March 2023
  • 115 Pages
  • Global
From
Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 140 Pages
  • Global
From
Metastatic Colorectal Cancer - Market Insight, Epidemiology and Market Forecast - 2032 - Product Thumbnail Image

Metastatic Colorectal Cancer - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • February 2022
  • 308 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Stivarga (regorafenib) is a drug used to treat metastatic colorectal cancer (mCRC). It is a multi-kinase inhibitor that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Stivarga is approved for use in combination with other chemotherapy drugs, and is used to treat patients who have already been treated with other chemotherapy drugs. It is also used to treat patients who have not responded to other treatments. Stivarga is manufactured by Bayer AG and is marketed in the United States by Merck & Co. It is also available in other countries, including Canada, Europe, and Japan. The drug is available in both oral and intravenous forms. In the Stivarga market, other companies include Pfizer, Novartis, and AstraZeneca. These companies offer similar drugs for the treatment of mCRC, such as Xeloda (capecitabine), Erbitux (cetuximab), and Vectibix (panitumumab). Show Less Read more